RxDoctor Payments Data

Chhabindra Nepal, MD

Internal Medicine · Lexington, KYNPI 1447650817

Payments from drug & device makers

$9,772in general payments, 2019–2025

Across 73 payments — averaging $133.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$9K
  • Sanofi-aventis U.S. LLC$181
  • AbbVie$162
  • AstraZeneca$156
  • GSK$134
  • United Therapeutics Corporation$123
  • plus $470 from 15 others

What the payments were for

  • Travel & lodging$1,90920%
  • Food & beverage$1,26513%
  • Education$6,22764%
  • Gifts$3714%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,772 in reported general payments places this provider in the 90th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$224,523
Medicare patients
430
Services billed
5,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter278$186,276
AdempasRiociguat12$169,323
Dupixent PenDupilumab17$71,481
Breo ElliptaFluticasone/Vilanterol135$63,338
NucalaMepolizumab13$55,657
Breztri AerosphereBudesonide/Glycopyr/Formoterol42$25,763
Spiriva RespimatTiotropium Bromide42$25,566
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr48$24,542
Stiolto RespimatTiotropium Br/Olodaterol Hcl32$19,292
Pirfenidone11$10,376
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate45$8,639
DuleraMometasone/Formoterol24$8,134
EliquisApixaban12$6,782
Advair HfaFluticasone Propion/Salmeterol18$6,624
Incruse ElliptaUmeclidinium Bromide12$5,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta$134$335,135486 claims
BayerAdempas$26$169,32312 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$54$44,85974 claims
AstraZenecaBreztri Aerosphere$156$25,76342 claims
PfizerEliquis$17$6,78212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →